Analysis
Pharma companies are also increasingly turning to AI to accelerate research and development.
1
Small biotech firms quicker to 'latch onto' AI than big ones: Tencent's Alex Ng
2
Himalaya Wealth Managers launches SME fund, eyes $52m corpus
3
EQT, Google Cloud join hands for AI rollout
4
South Korean government-led fund to invest $533m in FuriosaAI
5
HDFC Capital ropes in Development Bank of Japan as LP for real estate PE fund
More Stories
Private capital sponsors turn inward amid SE Asia’s exit slowdown
Vietnam’s Pharmacity secures growth capital from LeapFrog Investments
Australian govt’s impact investment vehicle commits $10m to Do Ventures Fund II
Hahn & Co weighs secondary sale in medical aesthetics company
Strategic exits to outpace IPOs in Vietnam’s F&B sector: Maestro Equity
Private Equity
The fund is targeting a gross IRR of over 20%.
Google engineers will work alongside EQT’s AI transformation team of about 35 people.
The firm has been valued at $2b in the latest round of funding.
H-DREAM has a target corpus of $500 million, with a greenshoe option of an additional $500 million.
Greater China
The Shanghai Futures Exchange is in the early stages of designing futures contracts for so-called AI tokens.
ByteDance currently sources CPUs from Intel and AMD.
The Fidelity China unit managed $663.10 million worth of assets as of the end of March.
Rest of Asia
The move comes two years after JIC took the firm private in a $6 billion deal.
Anthropic has roped in Sangeeta Bavi as the Head of Digital Natives, Startups and Growth for India.
